Skip to main content

Advertisement

Table 2 Cost-effectiveness and threshold prices under varying programmatic assumptions (2012 US$)*

From: Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices

   Cost per DALY averted at $0.25 per dose Microbicide threshold prices where $/infection averted (IA) = VMMC (~$1000/IA)
   2 doses per sex-act 1 dose per sex-act 2 gels per sex-act  
Baseline programme: 3 annual HIV tests, 3 gel collection visits   $297     $0.12  
Variations to distribution services        
HIV tests per year 2 $190 -36% -$29 -137% $0.19 49%
  4 $405 36% $186 137% $0.06 -49%
  6 $619 108% $401 411% Cannot be achieved  
Adherence counselling and gel collection visits 2 $272 -9% $53 -32% $0.14 12%
  6 $374 26% $155 97% $0.08 -35%
Integrated adherence counselling and gel collection into HIV testing (3)   $221 -26% $2 -97% $0.17 35%
  1. *Assuming 30% uptake after 10 years and trial consistency of gel use and mean imputed efficacy estimates, 10% product wastage during distribution, and a 3% discount rate on costs and effects.